NL-OMON36306已完成不适用
A multicenter Longitudinal Study for Disease Profiling of Asthma - Disease profiling asthma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy Subjects
- •Inclusion Criteria
- •Subjects must satisfy all of the following criteria to be enrolled in the study:
- •Must have signed an informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •Be willing and able to adhere to the study visit schedule and other protocol requirements.
- •Be between 18 and 55 years of age, inclusive, at informed consent.
- •Have no clinically significant abnormalities as determined by medical history, physical examination, blood chemistry assessments, hematologic assessments including complete blood count (CBC), urinalysis (see Attachment 2 for clinical laboratory analyses), measurement of vital signs, and ECG.
- •Have a body mass index (BMI) of less or equal to 32* kg/m2.
- •Must be able to produce an adequate induced sputum sample at screening, defined as a selected plug weight of at least 50 mg and a squamous cell count of < 20% (see Study Reference Manual).
- •Must be judged by the Principal Investigator (PI) to be a subject suitable to undergo bronchoscopy.
- •Have no history of chronic respiratory disease including asthma.
- •Have no history of allergic symptoms eg, allergic rhinitis, eczema.
- •Be a non-smoker for >= 1 year at initial screening visit and have <= 10 pack- year history of smoking.
- •No other acute illness in the 6 weeks prior to screening.
- •No contraindications to the procedures in this study including clinical or research bronchoscopy.
- •No bleeding disorder including use of anticoagulants and antiplatelet agents that could place the subjects at risk for bleeding. Able to abstain from aspirin use for 7 days and NSAID use for 3 daysprior to bronchoscopy without risk.
- •No contraindications to conscious sedation or medications used in the bronchoscopy procedure.
- •To participate in the optional genomic component of this study, subjects must have signed the informed consent for genomic research indicating willingness to participate in the genomic component of the study. Refusal to give consent for this component does not exclude a subject from participation in the study.;Subjects with Asthma
- •Inclusion Criteria for Asthmatic Subjects
- •Subjects must satisfy all of the following criteria to be enrolled in the study:
- •Must have signed an informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •Be willing and able to adhere to the study visit schedule and other protocol requirements.
- •Be between 18 and 70 years of age, inclusive, at informed consent. Subjects who elect to undergo bronchoscopy must be between 18 and 55 years old, inclusive, at informed consent.
- •Have no clinically significant abnormalities as determined by medical history, physical examination, blood chemistry assessments, hematologic assessments including CBC, urinalysis (see Attachment 2 for clinical laboratory analyses), measurement of vital signs, and ECG.
- •Have a BMI less then or equal to 32 kg/m2.
- •Must be able to produce an adequate induced sputum sample at screening, defined as a selected plug weight of at least 50 mg and a squamous cell count of < 20% (see Study Reference Manual).
- •Be a non-smoker for >= 1 year prior to screening and have <= 10 pack- year history of smoking.
- •No contraindications to the procedures in this stu
排除标准
- •Healthy Subjects
- •Exclusion Criteria
- •Subjects who meet any of the following criteria will be excluded from participating in the study:
- •Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study.
- •History of any clinically significant medical illness or medical disorders including (but not limited to) cardiovascular disease, neuromuscular, hematological disease including bleeding disorders, respiratory disease, hepatic or gastrointestinal (GI) disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.
- •Diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms.
- •Have a bronchodilator response of more or equal to 12% and at least 200 mL from baseline or an FEV1 value less than*85% of predicted value at screening.
- •A known history of sleep apnea requiring medical intervention.
- •Major or traumatic surgery within the 3 months prior to screening.
- •Have a positive urine pregnancy screening result.
- •Have a recent history (within previous 6 months) of alcohol or drug abuse.
- •Positive urine toxicology screen for substances of abuse, including but not limited to cannabinoids, cocaine, and methadone
- •. Positive urine toxicology screen, including but not limited to amphetamines, barbiturates, benzodiazepines, opiates and tricyclic antidepressants. unless the results can be reliably attributed to a concomitant prescription medication by the PI for a condition identified on medical history, in which case the subject may be enrolled after consultation with and agreement of the spnsors medical monitor
- •Have a positive urine screen for nicotine (urine cotinine test).
- •Have a positive breath test for alcohol at initial screening visit.
- •Have a positive serology test for HIV antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV) at screening.
- •Have a positive Phadiatop test.
- •Donated blood (volume >= *500 mL) within 56 days prior to screening.
- •Received an experimental antibody or biologic therapy within the 6 months prior to screening, or received any other experimental therapy or new investigational agent within 60 days or 5 half-lives (whichever is longer) of study start.
- •Be unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins.
- •Is an employee or employee family member of the investigator, study center, or Sponsor.
- •Any condition that, in the opinion of the investigator, would complicate or compromise the study, or the well-being of the subject.;Subjects with Asthma
- •Exclusion Criteria
- •Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study.
- •History of any clinically significant medical illness or medical disorders that place the subject at risk from participation by the judgment of the PI including (but not limited to) cardiovascular disease, neuromuscular, hematological disease including bleeding disorders, respiratory disease, hepatic or GI disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease. Subjects with stable, well
研究者
相似试验
已完成
不适用
Multicenter observational study for disease course and therapeutic outcomes in inflammatory bowel diseaseinflammatory bowel diseaseJPRN-UMIN000014602Osaka University Graduate School of Medicine1,000
进行中（未招募）
不适用
Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects with Primary Immunodeficiency (Japan Study)Primary Immune DeficiencyEUCTR2014-003409-13-Outside-EU/EEACSL Behring22
进行中（未招募）
1 期
ong-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersAtopic DermatitisEUCTR2019-001889-15-HUGalderma S.A.1,749
进行中（未招募）
1 期
ong-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2019-001889-15-FRGalderma S.A.1,300
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)Prurigo NodularisMedDRA version: 20.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-004294-13-SEGalderma S.A.508